Valbiotis SA (ALVAL.PA)
EUR 1.36
(-1.59%)
EUR 1.36
(-1.59%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 33.24 Million EUR | 22.37% |
| 2022 | 27.17 Million EUR | -4.59% |
| 2021 | 28.47 Million EUR | 35.6% |
| 2020 | 21 Million EUR | 39.86% |
| 2019 | 15.01 Million EUR | 26.11% |
| 2018 | 11.9 Million EUR | -6.34% |
| 2017 | 12.71 Million EUR | 682.76% |
| 2016 | 1.62 Million EUR | 40.12% |
| 2015 | 1.15 Million EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 Q2 | 24.94 Million EUR | 0.0% |
| 2023 Q4 | 33.3 Million EUR | 0.0% |
| 2023 FY | 33.24 Million EUR | 22.37% |
| 2022 FY | 27.17 Million EUR | -4.59% |
| 2022 Q2 | 23.35 Million EUR | 0.0% |
| 2022 Q4 | 27.17 Million EUR | 0.0% |
| 2021 FY | 28.47 Million EUR | 35.6% |
| 2021 Q4 | 28.47 Million EUR | 0.0% |
| 2021 Q2 | 32.4 Million EUR | 0.0% |
| 2020 Q4 | 21 Million EUR | 0.0% |
| 2020 Q2 | 16.48 Million EUR | 0.0% |
| 2020 FY | 21 Million EUR | 39.86% |
| 2019 Q2 | 11.38 Million EUR | 0.0% |
| 2019 Q4 | 15.01 Million EUR | 0.0% |
| 2019 FY | 15.01 Million EUR | 26.11% |
| 2018 FY | 11.9 Million EUR | -6.34% |
| 2018 Q4 | 11.9 Million EUR | 0.0% |
| 2018 Q2 | 11.06 Million EUR | 0.0% |
| 2017 Q2 | 14.01 Million EUR | 0.0% |
| 2017 Q4 | 12.71 Million EUR | 0.0% |
| 2017 FY | 12.71 Million EUR | 682.76% |
| 2016 Q4 | 1.62 Million EUR | 0.0% |
| 2016 FY | 1.62 Million EUR | 40.12% |
| 2015 FY | 1.15 Million EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| ABIONYX Pharma SA | 14.71 Million EUR | -126.023% |
| ABIVAX Société Anonyme | 327.06 Million EUR | 89.834% |
| Adocia SA | 24.95 Million EUR | -33.226% |
| Aelis Farma SA | 26.28 Million EUR | -26.51% |
| Biophytis S.A. | 11.93 Million EUR | -178.552% |
| Advicenne S.A. | 12.4 Million EUR | -167.978% |
| genOway Société anonyme | 31.84 Million EUR | -4.414% |
| IntegraGen SA | 8 Million EUR | -315.582% |
| Medesis Pharma S.A. | 1.92 Million EUR | -1625.972% |
| Neovacs S.A. | 47.53 Million EUR | 30.054% |
| NFL Biosciences SA | 3.97 Million EUR | -737.349% |
| Plant Advanced Technologies SA | 14.91 Million EUR | -122.948% |
| Quantum Genomics Société Anonyme | 3.74 Million EUR | -787.377% |
| Sensorion SA | 46.49 Million EUR | 28.49% |
| Theranexus Société Anonyme | 7.23 Million EUR | -359.37% |
| TME Pharma N.V. | 2.49 Million EUR | -1234.725% |
| TheraVet SA | 7.53 Million EUR | -341.295% |
| Valerio Therapeutics Société anonyme | 35.27 Million EUR | 5.744% |
| argenx SE | 4.11 Billion EUR | 99.191% |
| BioSenic S.A. | 9.55 Million EUR | -247.819% |
| Celyad Oncology SA | 16.28 Million EUR | -104.201% |
| DBV Technologies S.A. | 165.65 Million USD | 79.929% |
| Galapagos NV | 4.35 Billion EUR | 99.237% |
| Genfit S.A. | 173.87 Million EUR | 80.878% |
| GeNeuro SA | 6.31 Million EUR | -426.668% |
| Hyloris Pharmaceuticals SA | 47.68 Million EUR | 30.27% |
| Innate Pharma S.A. | 184.19 Million EUR | 81.949% |
| Inventiva S.A. | 69.13 Million EUR | 51.911% |
| MaaT Pharma SA | 42.93 Million EUR | 22.555% |
| MedinCell S.A. | 36.94 Million EUR | 10.014% |
| Nanobiotix S.A. | 93.89 Million EUR | 64.591% |
| Onward Medical N.V. | 43.62 Million EUR | 23.794% |
| Oryzon Genomics S.A. | 106.9 Million EUR | 68.898% |
| OSE Immunotherapeutics SA | 81.9 Million EUR | 59.404% |
| Oxurion NV | 6.55 Million EUR | -407.603% |
| Pharming Group N.V. | 426.33 Million EUR | 92.202% |
| Poxel S.A. | 4.82 Million EUR | -589.363% |
| GenSight Biologics S.A. | 9.08 Million EUR | -265.885% |
| Transgene SA | 45.21 Million EUR | 26.47% |
| Financière de Tubize SA | 1.92 Billion EUR | 98.269% |
| UCB SA | 15.53 Billion EUR | 99.786% |
| Valneva SE | 469.39 Million EUR | 92.917% |
| Vivoryon Therapeutics N.V. | 30.82 Million EUR | -7.847% |